Does Almond LDL Cholesterol Meta-Analysis work?

The current Migaku evidence database contains 2 reusable source documents for Almond LDL Cholesterol Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove. - Health Canada's Quality Appraisal Tool for Intervention Studies was used to assess each study's risk of bias. [Musa-Veloso K (2025); evidence level 1] - Almond consumption significantly reduced LDL-C (-0.132 mmol/L; 95% CI: -0.190, -0.075 mmol/L; p p p p = 0.001), LDL-C:HDL-C (-0.112; 95% CI: -0.199, -0.026; p = 0.011), ApoB (-4.552 mg/dL; 95% CI: -6.460, -2.645 mg/dL; p p = 0.006), with a borderline significant reduction in TG (-0.037 mmol/L; 95% CI: -0.079, 0.005; p = 0.085) and no effects on HDL-C, ApoA, or Lp[a]. [Musa-Veloso K (2025); evidence level 1] - Background/objectives While the benefits of almond consumption in reducing levels of TC and LDL-C are well established, the effects on additional lipids that have emerged as important predictors of cardiovascular disease, such as ApoB and the ratio of ApoB:ApoA, are not well characterized. [Musa-Veloso K (2025); evidence level 1] - In this systematic review and meta-analysis, the effects of almond consumption on blood lipids were comprehensively assessed. [Musa-Veloso K (2025); evidence level 1] - Conversely, a meta-analysis described in a report by the European Food Safety Authority (EFSA) on the tolerable upper intake level for dietary sugars identified a causal relationship with FS and risk of obesity and dyslipidemia from RCTs []. [Peregoy Jennifer A. (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.